Device Trial Radar · NCT04124588
Effectiveness of 'Nexpowder' for Hemostatic Treatments of Nonvariceal, Upper Gastrointestinal Bleeding
Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
348
Actual
Start
Nov 1, 2018
Primary completion
Oct 12, 2021
Study completion Nov 11, 2021
Sponsor
- Lead sponsor
- Next Biomedical Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 11, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, multi-center, randomized controlled trial to evaluate safety and effectiveness of endoscopic hemostatic powder, 'Nexpowder' for hemostatic treatments of nonvariceal upper gastrointestinal bleeding. This study is a prospective, multi-center, single blind (for patients), controlled investigation planned to evaluate safety and effectiveness of Nexpowder with 352 subject patients.
Conditions
- Nonvariceal Upper Gastrointestinal Bleeding
Interventions
Nexpowder (Hemostatic powder)Device
Nexpowder generates gelation-effects when the powder comes into contact with water, forms a physical barrier to control hemorrhage, preserve ulcer sites and thereby demonstrates its effective hemostatic performance. Hydrogels, which turned into gel-formation through water contacts in the gastrointestinal tract protect the wound sites for over 24 hours, are subsequently detached from the lesion, and completely excreted from the patient body system within 3 days.
Conventional TechniqueDevice
Argon Plasma Coagulation, Coagulation including Forcep, Hemoclipping, Band Ligation, Epinephrine or Absolute Alcohol Injecction can be used as standard-of-care hemostatic treatment(s).
Primary outcomes
What the sponsor says the trial is designed to measure.
- The rates of re-bleedingTime frame: 3 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Soon Chun Hyang University Bucheon Hospital
Gyeonggi-do, South Korea
Gachon Gil Hospital
Incheon, South Korea
Inha University Hospital
Incheon, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.